This is not the most recent version of the article. View current version (7 APR 2016)

Intervention Review

You have free access to this content

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis

  1. Larry C Lands1,*,
  2. Sanja Stanojevic2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 13 JUN 2013

Assessed as up-to-date: 23 MAY 2013

DOI: 10.1002/14651858.CD001505.pub3


How to Cite

Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD001505. DOI: 10.1002/14651858.CD001505.pub3.

Author Information

  1. 1

    Montreal Children's Hospital, Department of Pediatrics, Montreal, Quebec, Canada

  2. 2

    The Hospital for Sick Children, Child Health Evaluative Sciences & Respiratory Medicine, Toronto, Ontario, Canada

*Larry C Lands, Department of Pediatrics, Montreal Children's Hospital, 2300 Tupper Street, Montreal, Quebec, H3H-1PA, Canada. larry.lands@muhc.mcgill.ca.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 13 JUN 2013

SEARCH

This is not the most recent version of the article. View current version (07 APR 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Konstan 1991 {published data only}
Konstan 1995 {published data only}
  • Konstan MW. Systemic anti-inflammatory treatment NSAID [abstract]. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:L51.
  • Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine 1995;332(13):848-54.
  • Konstan MW, Davis PB, Byard PJ, Hoppel CJ. Results of a four-year, randomized, placebo-controlled, double-blind trial of high-dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology 1994;Suppl 10:S6.4.
Lands 2007 {published data only}
  • Lands LC, Corey M, Milner R, Kilcullen A, Cantin AM. High dose ibuprofen in CF children: the Trans-Canadian trial [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):276.
  • Lands LC, Milner R, Cantain AM, Manson D, Corey M. High-dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics 2007;151(3):249-54.
Shmarina 2004 {published data only}
  • Pukhalsky AL, Shmarina GV, Kaproanov NI, Kashirskaja NJ, Kokarovtseva SN, Shabalova LA, et al. Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):274.
  • Shmarina GV, Pukhalsky AL, Kashirskaja NJ. Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic) [abstract]. European Respiratory Journal 2004;24(Suppl 48):P3758.
Sordelli 1994 {published data only}
  • Sordelli DO, Macri CN, Maillie AJ. A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia [abstract]. Pediatric Pulmonology 1990;Suppl 5:215.
  • Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC. A preliminary study of the effect of anti-inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology 1994;7(2):109-17.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Chmiel 2007 {published data only}
  • Chmiel JF, Konstan MW, Lymp J, Mayer-Hamblett N, Hilliard KA, Accurso FJ, et al. Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF [abstract]. Pediatric Pulmonology 2007;42(Suppl 30):228.
Kovaleva 2000 {published data only}
  • Kovaleva LF, Guembitskaia TE, Gorbenko IA, Aleshin YuN. Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:155.
Noritake 1982 {published data only}
  • Noritake D, Hen J, Dolan TF. Effects of aspirin on pulmonary function in patients with cystic fibrosis [abstract]. Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:144.
  • Noritake DT, Hen J, Leo L, Dolan TF. The influence of aspirin on lung function in cystic fibrosis. Connecticut Medicine 1982;46:574-6.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Bertenshaw 2007
  • Bertenshaw C, Watson A, Lewis S, Smyth A. A survey of acute renal failure in cystic fibrosis patients in the United Kingdom. http://thorax.bmj.com/ (accessed 30 January 2007).
Chmiel 2002
Gibson 2003
Higgins 2003
Konstan 1990
  • Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. American Review of Respiratory and Critical Care Medicine 1990;141(1):186-92.
Konstan 1997
Konstan 1999
  • Konstan MW. Personal Communication 1999.
Konstan 2003
  • Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. Journal of Pharmacology and Experimental Therapeutics 2003;306(3):1086-91.
Konstan 2007
  • Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2007;176(11):1084-9.
Kovesi 1998
  • Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis (letter). New England Journal of Medicine 1998;338(1):65-6.
Li 2008
  • Li J, Xiang YY, Ye L, Tsui LC, Macdonald JF, Hu J, et al. Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. European Respiratory Journal 2008;32(2):334-43.
Rosenstein 1998
Southern 2004
Wheeler 1984
  • Wheeler WB, Williams RN, Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. Journal of Pediatrics 1984;104(5):685-99.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Dezateux 1999
Lands 2007
Lands 2009